

Disclosures

Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen Inc.	Stock	Significant (>= \$5,000)	Other
Edgewise Therapeutics, Inc.	Other - Scientific Advisory Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Lexicon Pharmaceuticals, Inc.	Other - Scientific Advisory Board	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sardocor Corp.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Space Exploration Technologies Corp.; aka, SpaceX	Other - Medical Advisor	Modest (< \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Medtronic, Inc.	Research/Research Grants <i>‡ Synchronizing cardiac cycle phase with foot strike to optimize LV performance in patients with advanced heart failure and cardiac resynchronization therapy (CRT).</i>	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2023	17-year old patient with hypertrophic cardiomyopathy who suffered sudden cardiac death.	Defendant <i>‡ Aaronson Rappaport Feinstein & Deutsch, LLP</i>	Provide record review and expert testimony if required on behalf of defendant (Dr. Ethan Rowin) and co-defendant (Atlantic Health System Hospital/Morristown Medical Center).	Modest (< \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/2/2024

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.